Evidence map›Paper›PMID 32915266›Full record

ArticleVirchows Archiv : an international journal of pathology2021

PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.

Nicoletta D'Alessandris, Innocenza Palaia, Angelina Pernazza, Federica Tomao, Anna Di Pinto, Lucia Musacchio, Martina Leopizzi, Valeria Di Maio, Irene Pecorella, Pierluigi Benedetti Panici and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Interplay Between Immune Microenvironment CD8Medicina (Kaunas, Lithuania) · 2025
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. What Can Trigger Spontaneous Regression of Breast Cancer?Diagnostics (Basel, Switzerland) · 2023
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Nicoletta D'AlessandrisDepartment of Radiological, Oncological, and Pathological Sciences, Sapienza University - Policlinico Umberto I, Viale Regina Elena 324, 00161, Rome, Italy. ndalessandris@gmail.com.
Innocenza PalaiaDepartment of Maternal and Child Health and Urological Sciences, Sapienza University - Policlinico Umberto I, Rome, Italy.
Angelina PernazzaDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University - Polo Pontino, Latin, Italy.
Federica TomaoDepartment of Maternal and Child Health and Urological Sciences, Sapienza University - Policlinico Umberto I, Rome, Italy.
Anna Di PintoDepartment of Maternal and Child Health and Urological Sciences, Sapienza University - Policlinico Umberto I, Rome, Italy.
Lucia MusacchioDepartment of Maternal and Child Health and Urological Sciences, Sapienza University - Policlinico Umberto I, Rome, Italy.
Martina LeopizziDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University - Polo Pontino, Latin, Italy.
Valeria Di MaioDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University - Polo Pontino, Latin, Italy.
Irene PecorellaDepartment of Radiological, Oncological, and Pathological Sciences, Sapienza University - Policlinico Umberto I, Viale Regina Elena 324, 00161, Rome, Italy.
Pierluigi Benedetti PaniciDepartment of Maternal and Child Health and Urological Sciences, Sapienza University - Policlinico Umberto I, Rome, Italy.
Carlo Della RoccaDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University - Polo Pontino, Latin, Italy.
Policlinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer immunotherapy has significantly improved the management of many malignancies in recent years. Although cervical cancer is the second most common women's cancer in the world, there are still few information about the role of checkpoint inhibitors in this neoplasm, especially in the neoadjuvant setting. In the present study, we retrieved 38 consecutive patients with squamous cell cervical cancer who underwent platinum-based neoadjuvant chemotherapy (NACT) followed by radical surgery. Pre-therapy biopsies were evaluated for the presence of tumor-infiltrating lymphocytes (TILs), including T (both cytotoxic CD8+ and helper CD4+) and B lymphocytes, macrophages, natural-killer cells, and eosinophils. Immunohistochemistry was performed to characterize the inflammatory cells and to evaluate programmed death-ligand 1 (PD-L1) expression on both neoplastic and inflammatory cells. We divided our study population in three groups using three cut-offs (< 10%, 10-40%, >40%), for both TILs and PD-L1 evaluation. Pathological response to NACT was obtained from the histological reports of the post-therapy surgical specimens. We observed that all cases showed stromal TILs, with a predominance of CD3+/CD4+ T helper cells, thus supporting the strong immunogenic potential of cervical cancer. The vast majority of neoplasms expressed PD-L1: 100% on immune cells and 92% on tumor cells. Firstly, we noticed that the percentage of neoplastic cells PD-L1+ was positively associated with high TIL percentage (p = 0.0073) and with increased PD-L1 expression on inflammatory cells (p = 0.0297). Secondly, we observed a significant correlation between both the percentage (p = 0.0105) of TILs and the expression of PD-L1 (p = 0.01045) on inflammatory cells and pathological response to NACT. These results suggest that cervical cancer could be a good target for immunotherapy, also in the neoadjuvant setting. Furthermore, PD-L1 expression was significantly associated with stromal TILs that interestingly may predict pathological response to NACT.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBiomarkers, TumorCarcinoma, Squamous CellChemotherapy, AdjuvantCisplatinClinical Decision-MakingDatabases, FactualFemaleHumansHysterectomyImmunohistochemistryImmunophenotypingLymphocytes, Tumor-InfiltratingB7-H1 AntigenBiomarkers, TumorCD274 protein, humanCisplatinPaclitaxelCervical cancerNeoadjuvant chemotherapyPD-L1Tumor-infiltrating lymphocytes

Identifiers

PMID32915266
OpenAlexW3086600256

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.